• Home
  • News
  • QVAR News from Teva Respiratory

QVAR News from Teva Respiratory

07 Aug 2017 1:29 PM | Anonymous

This morning, Teva announced that the U.S. Food and Drug Administration (FDA) has approved QVAR® RediHaler™ (beclomethasone dipropionate HFA) inhalation aerosol for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older. QVAR® RediHaler™ is not indicated for the relief of acute bronchospasm. As a partner, Teva Respiratory wanted to make us aware of this news as soon as it was made public.

QVAR® RediHaler™ differs from conventional metered-dose inhalers (MDIs) as it delivers medication via a breath-actuated MDI, eliminating the need for hand-breath coordination during inhalation. QVAR® RediHaler™ administers the same active drug ingredient found in QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol, with a different mode of delivery. In addition, QVAR® RediHaler™ is designed to be used without shaking or priming. It should not be used with a spacer or volume holding chamber.

 Teva plans to discontinue sales of the current QVAR® MDI formulation upon the launch of QVAR® RediHaler™ in the first quarter of 2018. Patients and caregivers are encouraged to speak with a healthcare professional about how this transition may impact their current treatment plan.

Please see Important Safety Information below and access to the full Prescribing Information at

70 Buckwalter Rd. Ste 900, #330, Royersford, PA 19468   |   Phone: 888-988-7747   |   Email:

Privacy Policy

Powered by Wild Apricot Membership Software